ZYXI Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -321.21% compared to 's net margin of -269.38%. 's return on equity of -709.17% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

has a consensus price target of $3.70, signalling upside risk potential of 2860%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 2309.64%. Given that has higher upside potential than Intelligent Bio Solutions, Inc., analysts believe is more attractive than Intelligent Bio Solutions, Inc..

has a beta of 0.987, which suggesting that the stock is 1.301% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

quarterly revenues are $13.4M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. 's net income of -$42.9M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, 's price-to-earnings ratio is 18.60x while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for is 0.04x versus 9.90x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -321.21% compared to 's net margin of -162.05%. 's return on equity of -709.17% beat Standard BioTools, Inc.'s return on equity of -24.44%.

has a consensus price target of $3.70, signalling upside risk potential of 2860%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 5.44%. Given that has higher upside potential than Standard BioTools, Inc., analysts believe is more attractive than Standard BioTools, Inc..

has a beta of 0.987, which suggesting that the stock is 1.301% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.

has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

quarterly revenues are $13.4M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. 's net income of -$42.9M is lower than Standard BioTools, Inc.'s net income of -$31.7M. Notably, 's price-to-earnings ratio is 18.60x while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for is 0.04x versus 4.32x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -321.21% compared to 's net margin of -25.94%. 's return on equity of -709.17% beat LENSAR, Inc.'s return on equity of -1013.45%.

has a consensus price target of $3.70, signalling upside risk potential of 2860%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 24.9%. Given that has higher upside potential than LENSAR, Inc., analysts believe is more attractive than LENSAR, Inc..

has a beta of 0.987, which suggesting that the stock is 1.301% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.

has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

quarterly revenues are $13.4M, which are smaller than LENSAR, Inc. quarterly revenues of $14.3M. 's net income of -$42.9M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, 's price-to-earnings ratio is 18.60x while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for is 0.04x versus 2.41x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Yijia Group Corp. has a net margin of -321.21% compared to 's net margin of 8.38%. 's return on equity of -709.17% beat Yijia Group Corp.'s return on equity of 55.22%.

has a consensus price target of $3.70, signalling upside risk potential of 2860%. On the other hand Yijia Group Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that has higher upside potential than Yijia Group Corp., analysts believe is more attractive than Yijia Group Corp..

has a beta of 0.987, which suggesting that the stock is 1.301% less volatile than S&P 500. In comparison Yijia Group Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yijia Group Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. pays -- of its earnings as a dividend. Yijia Group Corp. pays out -- of its earnings as a dividend.

quarterly revenues are $13.4M, which are larger than Yijia Group Corp. quarterly revenues of $427.1K. 's net income of -$42.9M is lower than Yijia Group Corp.'s net income of $35.8K. Notably, 's price-to-earnings ratio is 18.60x while Yijia Group Corp.'s PE ratio is 46.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for is 0.04x versus 14.42x for Yijia Group Corp.. Usually stocks with elevated PS ratios are considered overvalued.